Head-To-Head Analysis: Actinium Pharmaceuticals (NYSE:ATNM) versus Comera Life Sciences (NASDAQ:CMRA)

Comera Life Sciences (NASDAQ:CMRA) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Institutional and Insider Ownership

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Comera Life Sciences and Actinium Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Comera Life Sciences	$1.00 million	0.00	-$18.00 million	($0.49)	N/A
Actinium Pharmaceuticals	$90,000.00	415.95	-$48.82 million	($1.10)	-1.09

Comera Life Sciences has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Comera Life Sciences and Actinium Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Comera Life Sciences	0	0	0	0	0.00
Actinium Pharmaceuticals	0	0	1	0	3.00

Actinium Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 233.33%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Comera Life Sciences.

Profitability

This table compares Comera Life Sciences and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Comera Life Sciences	N/A	N/A	N/A
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Volatility & Risk

Comera Life Sciences has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.31, indicating that its share price is 131% less volatile than the S&P 500.

Summary

Comera Life Sciences beats Actinium Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Comera Life Sciences

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.